Monday, March 3, 2025

Venture Global, Inc. Announces Record Date for Cash Dividend

  (BUSINESS WIRE) -- The Venture Global, Inc. (“Venture Global”) (NYSE: VG) board of directors determined today that the per share amount of its previously declared cash dividend shall be $0.0165 per share, or approximately $40 million in the aggregate, payable on March 31, 2025 to holders of its outstanding Class A common stock and outstanding Class B common stock, and that the record date shall be the close of business on March 10, 2025.


About Venture Global

Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s first facility, Calcasieu Pass, commenced producing LNG in January 2022. The company’s second facility, Plaquemines LNG, achieved first production of LNG in December 2024. The company is currently constructing and developing over 100 MTPA of nameplate production capacity to provide clean, affordable energy to the world. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.




View source version on businesswire.com: https://www.businesswire.com/news/home/20250228270873/en/



Permalink

https://www.aetoswire.com/en/news/0103202545127


Contacts

Investor Contact

Michael Pasquarello

IR@ventureglobalLNG.com


Media Contact

Shaylyn Hynes

press@ventureglobalLNG.com

Radisys Expands Small Cell Portfolio with Qualcomm Dragonwing FSM200 Platform for FR1 and FR2

 DALLAS - Friday, 28. February 2025


New solution portfolio with advanced features addresses multiple indoor and outdoor market segments


(BUSINESS WIRE) -- Radisys® Corporation, a global leader of open telecom solutions, announced the availability of its award-winning Connect RAN software on the Qualcomm Dragonwing™ FSM200 Platform for both FR1 and FR2. The solution leverages baseband and advanced Radio capabilities of the Dragonwing FSM200 platform to address high performance/capacity use cases with advanced features required in various market segments, including MNOs, enterprise, Fixed Wireless Access (FWA), private 5G, Industry 4.0 and home networks. Radisys Connect RAN software on the Qualcomm Dragonwing™ FSM100 platform is already globally deployed for various use cases.


Radisys' Connect RAN 5G solution offers a comprehensive feature set, fully interoperable with a wide ecosystem and robust manageability support, enabling customers to deploy small cells in multiple verticals at reduced operational and capital expenses with a quick time-to-market.


Highlights


Radisys demonstrated continued leadership in mmWave RAN on Dragonwing FSM100 and FSM200 platforms with support for bandwidth up to 800MHz, beamforming, network slicing, QoS, robust cryptography, and low latency support.


With optimized latency, support for Redcap devices, and Ethernet PDU functionality, the Connect RAN software meets the essential requirements of the Industry 4.0 market segment.


Enhanced low-footprint RAN software ported on Qualcomm Dragonwing™ QIP100 Infrastructure Processor provides a cost-effective solution for home femto deployments.


Enables a diverse range of indoor and outdoor options with various bands and bandwidth combinations, including CBRS.


With support for TR-069/TR-196, NETCONF, and O-RAN O1 interfaces, the RAN software solution provides comprehensive FCAPS manageability, ensuring seamless integration with both legacy ACS deployments and newer O-RAN O1-based SMO/management systems.


Radisys’ solution also supports the ORAN E2 interface towards the RIC, enabling AI capabilities even in small cell deployments.


“Qualcomm Technologies, Inc. is pleased to continue working with Radisys in supporting a thorough ecosystem to help customers rapidly create and deploy small cells,” said Gerardo Giaretta, Vice President, Product Management, Qualcomm Technologies, Inc. “Our collaboration with Radisys is expanding 5G network capabilities with advanced features and enabling network access across our global customer base.”


“By expanding our collaboration with Qualcomm Technologies to now use the Dragonwing FSM200 Platform, Radisys is innovating advancements in small cell solutions,” said Munish Chhabra, SVP and General Manager, Software and Services at Radisys. “With Radisys’ advanced software portfolio together with Qualcomm Technologies’ baseband, we’re pleased to provide customers with multiple options to deploy small cells across industry verticals.”


About Radisys


Radisys is a global leader in open telecom solutions and services. Its disaggregated platforms and integration services leverage open reference architectures and standards combined with open software and hardware, enabling service providers to drive open digital transformation. Radisys offers an end-to-end solutions portfolio from digital endpoints to disaggregated and open access and core solutions, to immersive digital applications and engagement platforms. Its world-class and experienced network services organization delivers full lifecycle services to help service providers build and operate highly scalable and high-performance networks at optimum total cost of ownership. For more information, visit www.Radisys.com/.


Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.


Qualcomm, FSM, and Qualcomm Dragonwing are trademarks or registered trademarks of Qualcomm Incorporated.


Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250228637650/en/



Permalink

https://www.aetoswire.com/en/news/2802202545113


Contacts

Nereus for Radisys

Matt Baxter, +1-503-619-0505

radisys@nereus-worldwide.com


 

Sunday, March 2, 2025

SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order

  BEIJING - Friday, 28. February 2025 AETOSWire  



(BUSINESS WIRE) -- Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) from the Privy Council following the previously announced Privy Council Judgment (the “Judgment”) which ruled, among others, that (i) the slate of nominees proposed by a group of shareholders at the 2018 Annual General Meeting was rightfully elected to the board of directors of SINOVAC and (ii) the Company’s Rights Agreement (also known as poison pill agreement) was invalid. Upon the receipt of the Order, SINOVAC has begun to implement the Judgment and the Order.


As the Company's Rights Agreement is void, all the exchange shares issued pursuant to the Rights Agreement (the “Exchange Shares”), including 27,777,341 common shares and all 14,630,813 Convertible Series B Preferred Shares of SINOVAC, held by the 2019 Rights Exchange Trust, are void and will be cancelled.


The current members of the new SINOVAC Board of Directors (the “New Board”) are Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Dr. David Guowei Wang, Mr. Pengfei Li and Mr. Jianzeng Cao. The New Board has determined that Dr. Chiang Li, Mr. Yuk Lam Lo, and Dr. David Guowei Wang, constituting three of the five directors, are independent directors. Mr. Lo and Dr. Wang are the members of the New Board’s Audit Committee. Dr. Li, Mr. Lo and Dr. Wang are the members of the New Board’s Compensation Committee and the Corporate Governance and Nominating Committee. The New Board will need to appoint a third member for the Audit Committee to meet the Nasdaq Rule 5605 requirement. The executive management of SINOVAC remains unchanged.


SINOVAC’s New Board is committed to acting in the best interests of the Company as well as maximizing the value for all shareholders. Under the leadership of the New Board, the Company is determined to maintain transparency and uphold high standards of corporate governance.


As a result of the invalid poison pill agreement implemented by the former directors, trading in SINOVAC’s shares has been halted over the past six years. The New Board is in communication with Nasdaq and is working diligently to respond to Nasdaq’s questions and requests so as to provide for continued listing of the Company’s shares. Moreover, the New Board has initiated the process to cancel invalid Exchange Shares and to determine the valid shares issued and outstanding in order to achieve trading resumption.


The Company will also provide a business update in due course.


About the Judgment from the Privy Council


Enclosed for your information is a link to the full text of the Judgment: https://jcpc.uk/uploads/jcpc_2022_0041_0062_judgment_d94de5cc2a.pdf


About SINOVAC


Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.


SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.


The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.


SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.


SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.


For more information, please visit the Company’s website at www.sinovac.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250225390774/en/



Permalink

https://www.aetoswire.com/en/news/2802202545112


Contacts

Sinovac Biotech Ltd.

Helen Yang

Tel: +86-10-8279 9779

Email: ir@sinovac.com

ITB 2025: Egypt Strengthens Tourism Ties with Germany at Berlin Fair

 BERLIN - Friday, 28. February 2025 AETOSWire  



Historic opening of the Grand Egyptian Museum, July 3rd, 2025

Egypt’s Diversity: A Gem of History, Adventure, Nature, and Wellness.

The number of international visitors to Egypt increased by 5% in 2024.

 


(BUSINESS WIRE) -- Egypt’s Minister of Tourism and Antiquities, Sherif Fathi, will present Egypt’s new tourism strategy at the ITB Berlin international travel trade fair, highlighting Germany’s pivotal role in the sector’s development. Germany continues to be Egypt’s largest source of visitors. In 2024, 1.7 million German tourists traveled to Egypt, marking a 5% increase from the previous year. “We are confident that the number of visitors will continue to rise in 2025,” stated Fathi, who has served as Minister of Tourism and Antiquities since July 2024. This will be his first ITB Berlin appearance as Minister.


In 2024, approximately 15.7 million international travelers visited Egypt—a 5% increase from the previous year—underscoring the country’s strategic vision of attracting 30 million tourists annually by 2030.


Egypt’s Tourism Highlights: History and Culture


Egypt is one of the world’s most popular travel destinations, renowned for its rich history, diverse culture, and breathtaking landscapes. The legacy of the pharaohs, including the last surviving Wonder of the Ancient World, attracts visitors passionate about history and ancient civilizations. The Red Sea, with its crystal-clear waters, is a top destination for divers and families alike. With world-class accommodations at affordable prices and excellent international flight connections, Egypt continues to be a premier travel hotspot.


The anticipated full opening of the Grand Egyptian Museum on July 3rd—the largest museum in the world dedicated to a single civilization—will be a highlight of this year. After three decades of planning and restoration, the museum partially opened on October 16, 2024. While some sections remain under development, visitors can already explore the Grand Hall, staircases, gardens, and select exhibition spaces. During the museum’s pre-opening phase in 2024, more than 300,000 guests visited its main halls.


Health and Wellness


Egypt has also emerged as a leading destination for health and wellness tourism. From luxury resorts on the Red Sea to remote desert oases, the country offers world-class wellness experiences. Known for its mineral-rich hot springs and therapeutic waters, Egypt provides treatments for various ailments, including skin conditions, respiratory diseases, and rheumatism. Notable wellness destinations include:


Siwa Oasis, home to over 200 natural springs used for healing treatments.


Bahariya and Kharga Oases, featuring sulfur-rich thermal waters.


Aswan, known for its prestigious spa resorts such as Kato Doo Wellness and The Zen Wellness.


Sustainable Tourism Development


Egypt is committed to sustainable development of its tourism infrastructure and the preservation of its cultural heritage. Protecting the Red Sea’s unique biodiversity is a central pillar of Egypt’s responsible tourism strategy. Environmental certification programs for resorts play an integral role in these efforts, particularly in coastal regions stretching from El Gouna to Marsa Alam.


As one of the key participants at ITB Berlin 2025, Egypt's Tourism Authority invites journalists to the following press conference:


Date: Tuesday, March 4, 2025


Time: 15:00 hrs


Location: Messe Berlin Booth M4, CityCube Messedamm 22, 14055 Berlin


For more information, visit: https://www.experienceegypt.eg/en


About the About the Egyptian Tourism Authority


The Egyptian Tourism Authority (ETA) was established in 1981 to boost international tourism by highlighting Egypt's long history and promoting the country’s many tourist attractions. The ETA's mission also includes increasing domestic tourism, raising awareness of tourism throughout the country, and strengthening the connection between Egyptians and their heritage. The ETA focuses on the diversity of attractions and destinations within Egypt and on developing marketing strategies and programmes to promote tourism, as well as providing technical and marketing support. It also organises and sponsors touristic, sporting, social and cultural events throughout the country. The ETA Board of Directors is chaired by the Minister of Tourism.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20250227385390/en/



Permalink

https://www.aetoswire.com/en/news/2802202545107


Contacts

Kamila Giraldo

Account Manager

e-mail: egypttourism@mcgroup.com

Allianz Achieves Record Operating Profit of 16.0 Billion Euros


 New Share Buy-Back of up to 2 Billion Euros Announced

(BUSINESS WIRE) -- February 28, 2025

12M 2024:

  • Total business volume rises 11.2 percent to 179.8 billion euros

  • Operating profit increases by 8.7 percent to 16.0 billion euros supported by all business segments

  • Shareholders’ core net income advances 10.1 percent to 10.0 billion euros

  • Strong Solvency II capitalization ratio of 209 percent

4Q 2024:

  • Total business volume advances 16.0 percent to 45.9 billion euros

  • Operating profit increases 10.9 percent and reaches 4.2 billion euros, mainly attributable to very good results in the Property-Casualty segment

  • Shareholders’ core net income rises 3.5 percent to 2.4 billion euros

Outlook:

  • For 2025, Allianz targets an operating profit of 16.0 billion euros, plus or minus 1 billion euros1

Other:

  • Management to propose a dividend per share of 15.40 euros, an increase of 11.6 percent from 2023

  • A new share buy-back program of up to 2 billion euros has been announced

As always, natural catastrophes and adverse developments in the capital markets, as well as factors stated in our cautionary note regarding forward-looking statements may severely affect the operating profit and/or net income of our operations and the results of the Allianz Group.

“In 2024, Allianz delivered another set of record financial results, which are underpinned by strong performance across all segments, consistently high customer satisfaction, and record employee engagement. Allianz remains the trusted partner of choice for our customers in a global context in which above-average levels of natural catastrophes, armed conflicts, and deepening polarization continue to create considerable volatility.

These conditions elevate the need for what Allianz offers its customers and the world: a more secure future that translates into greater prosperity. Our renewed strategy, recently announced at our Capital Markets Day, underscores our conviction in growth and our confidence in our resilience and our capabilities. As we realize the value of our deepening customer relationships, we lift our ambitions to deliver even higher capital-efficient growth in the quarters and years ahead.”

- Oliver Bäte, Chief Executive Officer of Allianz SE

FINANCIAL HIGHLIGHTS

Total business volume

12M 2024: Total business volume increased strongly by 11.2 percent to 179.8 billion euros. Adjusted for foreign currency translation and consolidation effects, internal growth was 11.9 percent. Our Life/Health business was the main growth driver, with strong contribution also from our Property-Casualty segment.

4Q 2024: Total business volume growth of 16.0 percent to 45.9 billion euros was excellent. Adjusted for foreign currency translation and consolidation effects, internal growth reached 16.2 percent, further accelerating from an already strong performance in the first nine months (9M 2024: 11.1 percent). The Life/Health segment was the main growth driver, while our Property-Casualty business also contributed strongly.

Earnings

12M 2024: Operating profit was excellent at 16.0 (12M 2023: 14.7) billion euros, an increase of 8.7 percent. All business segments contributed, with our Property-Casualty business being the main driver.

Shareholders’ core net income advanced by 10.1 percent to a very strong level of 10.0 billion euros, driven by operating profit growth and a higher non-operating result.

Net income attributable to shareholders increased by 16.3 percent to 9.9 (8.5) billion euros.

Core earnings per share (EPS)2 rose to 25.42 (22.61) euros.

The core return on equity (RoE)2 improved to 16.9 percent (16.1 percent).

The Board of Management proposes a dividend per share of 15.40 euros for 2024, an increase of 11.6 percent from 2023.

On February 27, 2025, Allianz has announced a new share buy-back program of up to 2 billion euros.

4Q 2024: Operating profit was excellent at 4.2 (4Q 2023: 3.8) billion euros. The strong increase of 10.9 percent was primarily driven by the Property-Casualty business but all segments contributed.

Shareholders’ core net income was 2.4 (2.4) billion euros, an increase of 3.5 percent.

Net income attributable to shareholders rose to 2.5 (2.2) billion euros, driven by a higher operating profit and a better non-operating result.

2 Core EPS and core RoE calculation based on shareholders‘ core net income.

Solvency II capitalization ratio

The Solvency II capitalization ratio remained at a strong level of 209 percent at the end of 2024 (3Q 2024: 209 percent3).

3 Based on quarterly dividend accrual; additional accrual to reflect FY dividend would impact Solvency II capitalization ratio by -3%-p as of September 30, 2024.

SEGMENTAL HIGHLIGHTS

“Allianz’s excellent results for 2024 and the consistency of our delivery once again underline our ability to create sustainable value for all the stakeholders invested in our success.

In an environment of muted economic growth and significant levels of natural catastrophes we have achieved record operating profit and net income. All segments finished the year above their operating profit target mid-points, which demonstrates the resilience of our business model.

Building on our strong foundations, we enter 2025 with confidence. We have lifted our ambitions at our Capital Markets Day in December and are committed to continue generating attractive returns for our shareholders.”

- Claire-Marie Coste-Lepoutre, Chief Financial Officer of Allianz SE

Property-Casualty insurance: Double-digit operating profit growth

12M 2024: Total business volume increased by 8.3 percent to 82.9 (76.5) billion euros. Adjusted for foreign currency translation and consolidation effects, internal growth was very good at 8.2 percent.

Retail, SME & Fleet achieved strong internal growth of 9 percent, lifting total business volume to 50.2 (45.9) billion euros while Commercial advanced 7 percent, increasing total business volume to 32.7 (30.3) billion euros.

Operating profit rose by 14.3 percent to an excellent level of 7.9 (6.9) billion euros, well exceeding the operating profit outlook mid-point of 7.3 billion euros. A better operating insurance service result and a higher operating investment result were the main drivers.

The combined ratio improved to 93.4 percent (93.8 percent). The loss ratio was 69.3 percent (69.3 percent) as lower natural catastrophe losses and underlying improvements were offset by less run-off. The expense ratio developed favorably by 0.4 percentage points to 24.2 percent and continued its positive trajectory.

In Retail, SME & Fleet, the combined ratio improved by 1.7 percentage points to 94.1 percent. The Commercial combined ratio was at a very good level of 92.2 percent (90.5 percent).

4Q 2024: Total business volume rose by 11.0 percent to 19.5 (17.6) billion euros. Adjusted for foreign currency translation and consolidation effects, internal growth was strong at 10.9 percent.

Retail, SME & Fleet and Commercial achieved excellent internal growth of 11 percent and 14 percent, respectively, generating total business volumes of 12.1 (11.0) billion euros in Retail, SME & Fleet and 7.4 (6.5) billion euros in Commercial.

Operating profit increased by 21.2 percent to 1.9 (1.6) billion euros mainly driven by higher operating investment and insurance service results.

The combined ratio improved to 94.7 percent (94.9 percent). The loss ratio developed favorably and reached 70.7 percent (71.4 percent), supported by a very good attritional loss ratio. The expense ratio was 24.1 percent (23.5 percent).

In Retail, SME & Fleet, the combined ratio developed favorably by 2.4 percentage points to 94.0 percent. In Commercial it reached 96.6 percent (92.9 percent).

Life/Health insurance: Excellent performance

12M 2024: PVNBP, the present value of new business premiums, increased strongly by 21.6 percent to 81.8 (67.3) billion euros, driven by growth in almost all entities.

The new business margin (NBM) was attractive at 5.7 percent (5.9 percent) and the value of new business (VNB) advanced to 4.7 (4.0) billion euros.

Operating profit increased to a strong level of 5.5 (5.2) billion euros, surpassing the operating profit outlook mid-point of 5.2 billion euros. This performance was supported by positive developments in most regions.

Contractual Service Margin (CSM) advanced from 52.6 billion euros at the end of 2023 to 55.6 billion euros4, mainly due to strong normalized CSM growth of 6.1 percent5.

4Q 2024: PVNBP rose significantly by 26.9 percent to 21.2 (16.7) billion euros, driven by higher volumes in most entities.

The new business margin was healthy at 5.5 percent (5.9 percent), and the value of new business grew strongly to 1.2 (1.0) billion euros.

Operating profit was at an excellent level of 1.4 (1.4) billion euros.

Contractual Service Margin rose from 54.2 billion euros4 at the end of the third quarter to 55.6 billion euros4 mainly driven by a good normalized CSM growth of 1.4 percent5.

4 Includes gross CSM of 0.8 billion euros (as of September 30, 2024, and as of December 31, 2024), for UniCredit Allianz Vita S.p.A., which was classified as held for sale in the third quarter of 2024.

5 Excluding effects from a fund merger in Italy.

Asset Management: Strong net inflows and third-party AuM growth

12M 2024: Operating revenues increased to 8.3 (8.1) billion euros, internal growth was at 3.1 percent. This was driven by higher AuM-driven revenues.

Operating profit rose to a good level of 3.2 (3.1) billion euros, up 3.6 percent, and exceeding the full-year outlook mid-point of 3.1 billion euros. Adjusted for foreign currency translation effects, operating profit advanced by 3.7 percent. Excluding the impact from performance fees, the operating profit increases strongly by 11 percent.

The cost-income ratio (CIR) improved to 61.1 percent (61.3 percent).

Third-party assets under management increased by 208 billion euros from the end of 2023 to 1.920 trillion euros as of December 31, 2024. Strong net inflows of 84.8 billion euros, almost four times the prior year level, were the biggest contributor.

4Q 2024: Operating revenues rose to 2.4 (2.3) billion euros, internal growth was at 1.3 percent. The increase was mainly due to higher AuM-driven revenues.

Operating profit amounted to an excellent level of 941 (912) million euros. Adjusted for foreign currency translation effects, operating profit grew by 2.7 percent. Excluding the impact of performance fees, the operating profit rose 21 percent.

The cost-income ratio (CIR) developed favorably to 60.0 percent (60.5 percent).

Third-party assets under management increased to 1.920 trillion euros as of December 31, 2024, up by 80 billion euros from the end of the third quarter 2024. Favorable foreign currency translation effects as well as good net inflows of 16.7 billion euros were the main drivers.

4Q & FY 2024 RESULTS TABLE

Allianz Group - preliminary key figures 4th quarter and fiscal year 2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4Q
2024

 

4Q
2023

 

Delta

 

 

12M 2024

 

12M 2023

 

Delta

 

Total business volume

  

€ bn

 

45.9

 

39.6

 

16.0%

 

 

179.8

 

161.7

 

11.2%

 

- Property-Casualty

 

 

 

€ bn

 

19.5

 

17.6

 

11.0%

 

 

82.9

 

76.5

 

8.3%

 

- Life/Health

 

 

 

€ bn

 

24.3

 

20.0

 

21.5%

 

 

89.3

 

77.9

 

14.7%

 

- Asset Management

 

  

€ bn

 

2.4

 

2.3

 

2.0%

 

 

8.3

 

8.1

 

3.0%

 

- Consolidation

 

 

€ bn

 

-0.3

 

-0.3

 

-12.7%

 

 

-0.7

 

-0.8

 

-6.1%

 

Operating profit / loss

 

 

 

€ mn

 

4,174

 

3,765

 

10.9%

 

 

16,023

 

14,746

 

8.7%

 

- Property-Casualty

 

 

 

€ mn

 

1,948

 

1,608

 

21.2%

 

 

7,898

 

6,909

 

14.3%

 

- Life/Health

 

 

 

€ mn

 

1,424

 

1,362

 

4.5%

 

 

5,505

 

5,191

 

6.0%

 

- Asset Management

 

 

 

€ mn

 

941

 

912

 

3.2%

 

 

3,239

 

3,126

 

3.6%

 

- Corporate and Other

 

 

 

€ mn

 

-140

 

-115

 

21.1%

 

 

-615

 

-474

 

29.9%

 

- Consolidation

   

€ mn

 

1

 

-1

 

n.m.

 

 

-4

 

-7

 

-35.5%

 

Net income

 

 

 

€ mn

 

2,636

 

2,255

 

16.9%

 

 

10,540

 

9,032

 

16.7%

 

- attributable to non-controlling interests

 

€ mn

 

163

 

104

 

56.9%

 

 

609

 

491

 

24.0%

 

- attributable to shareholders

 

 

€ mn

 

2,472

 

2,151

 

14.9%

 

 

9,931

 

8,541

 

16.3%

 

Shareholders’ core net income1

 

€ mn

 

2,434

 

2,351

 

3.5%

 

 

10,017

 

9,101

 

10.1%

 

Core earnings per share2

 

 

6.31

 

6.00

 

5.1%

 

 

25.42

 

22.61

 

12.4%

 

Dividend per share

  

 

 

 

 

 

15.40

3

13.80

 

11.6%

 

Additional KPIs

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

- Group

 

Core return on equity4

 

%

 

 

 

 

 

16.9%

 

16.1%

 

0.8%

-p

- Property-Casualty

 

Combined ratio

 

%

 

94.7%

 

94.9%

 

-0.2%

-p

 

93.4%

 

93.8%

 

-0.4%

-p

- Life/Health

 

New business margin

 

%

 

5.5%

 

5.9%

 

-0.5%

-p

 

5.7%

 

5.9%

 

-0.2%

-p

- Asset Management

 

Cost-income ratio

 

%

 

60.0%

 

60.5%

 

-0.5%

-p

 

61.1%

 

61.3%

 

-0.2%

-p

 

 

 

 

 

 

 

 

 

 

 

 

 

12/31/2024

 

12/31/2023

 

Delta

 

Shareholders' equity5

 

 

 

€ bn

 

 

 

 

 

 

 

 

60.3

 

58.2

 

3.5%

 

Contractual service margin (net)6

 

€ bn

 

 

 

 

 

 

 

 

34.5

 

32.7

 

5.6%

 

Solvency II capitalization ratio7

 

%

 

 

 

 

 

 

 

 

209%

 

206%

 

3%

-p

Third-party assets under management

 

  

€ bn

 

 

 

 

 

 

 

 

1,920

 

1,712

 

12.1%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Please note: The figures are presented in millions of Euros, unless otherwise stated. Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

1_

Presents the portion of shareholders’ net income before non-operating market movements and before amortization of intangible assets from business combinations (including any related income tax effects).

2_

Calculated by dividing the respective period’s shareholders' core net income, adjusted for net financial charges related to undated subordinated bonds classified as shareholders' equity, by the weighted average number of shares outstanding (basic core EPS).

3_

Proposal.

                 

4_

Represents the ratio of shareholders’ core net income to the average shareholders’ equity at the beginning and at the end of the year. Shareholders’ core net income is adjusted for net financial charges related to undated subordinated bonds classified as shareholders’ equity. From the average shareholders’ equity, undated subordinated bonds classified as shareholders’ equity, unrealized gains and losses from insurance contracts and other unrealized gains and losses are excluded. Due to an adjustment of prior periods comparative figures for the balance sheet, the core RoE changed by +0.1%-p compared to the published figure as of 31 December 2023.

5_

Excluding non-controlling interests. In 1Q 2024 Allianz reclassified certain minority interests between equity and liabilities. Prior periods comparative figures for the balance sheet have been adjusted with a minor impact on shareholders’ equity only (reduced by EUR 0.2bn as of 31 December 2023).

6_

Includes net CSM of EUR 0.3bn as of 31 December 2024, for UniCredit Allianz Vita S.p.A., which was classified as held for sale in the 3Q 2024.

7_

Risk capital figures are group diversified at 99.5% confidence level. Including the application of transitional measures for technical provisions, the Solvency II capitalization ratio amounted to 229% as of 31 December 2023. As of 31 December 2024, the application of transitional measures for technical provisions had no impact on the Solvency II capitalization ratio.

RELATED LINKS